Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Ahmed Obeidat MD, PhD

Ahmed Obeidat MD, PhD

Associate Professor, Department of Neurology, Neuroimmunology, and Multiple Sclerosis; Director, Neuroimmunology and MS Fellowship Program, The Medical College of Wisconsin

Dr. Ahmed Obeidat is a neurologist in Milwaukee, Wisconsin, affiliated with the Froedtert and Medical College of Wisconsin health network and working with adults in diagnosing and managing multiple sclerosis and immune disorders of the central nervous system. He is an associate professor in neurology, neuroimmunology, and multiple sclerosis at the Medical College of Wisconsin and the founding director of the neuroimmunology and multiple sclerosis fellowship program. 

Dr. Obeidat’s research aims to advance understanding of the causes of MS and to improve the efficacy and safety of current MS therapeutics. As such, he is the current principal investigator on more than 20 therapeutic clinical trials in MS and related disorders. He has published over 80 peer-reviewed articles and abstracts. He is the editor-in-chief for Generations (a publication of the Consortium of Multiple Sclerosis Centers [CMSC]) and serves on the editorial boards of the International Journal of MS Care and Frontiers in Neurology.

Dr. Obeidat received his medical degree from the Jordan University of Science and Technology in 2008. He then joined the graduate program in neuroscience and physiology at Wright State University in Dayton, Ohio, where he received a PhD in biomedical sciences in 2013. He completed his neurology residency at the University of Cincinnati in 2017 as well as fellowship training in demyelinating diseases and neuroimmunology, also from the University of Cincinnati, in 2018.


Dr. Obeidat received speaking or consulting fees from Alexion, Banner Life Sciences, Biogen, Biologix, Bristol Myers Squibb, Celgene, EMD Serono, Genentech, GW Pharma, Horizon Therapeutics, Jazz Pharma, Novartis, Sanofi/Genzyme, Sandoz Pharmaceuticals, TG therapeutics, VielaBio and Honoraria from Medscape and MJH Life Sciences.